Melanoma treatment market projected to surge to USD 12.4 billion by 2035, driven by breakthrough immunotherapies and precision medicine
[New York, 17th June 2025] – The global melanoma treatment market is poised for transformative growth, projected to expand from USD 5.2 billion in 2023 to USD 12.4 billion by 2035, at a CAGR of 10.8%, according to Clearview Market Insights. This growth is driven by revolutionary advancements in immune checkpoint inhibitors, targeted therapies, and AI-driven diagnostics, reshaping outcomes for late-stage melanoma patients.
Request Sample @ https://clearviewmarketinsights.com/report-details/global-melanoma-treatment-market/
Key Growth Catalysts
1. Immunotherapy Dominance:
o PD-1 inhibitors (Keytruda, Opdivo) now account
for 58% of revenue in 2024, with 5-year survival rates doubling
to 40% for metastatic melanoma.
o Pipeline Boom: Over 120 clinical trials are
underway for next-generation CTLA-4/PD-L1 combinations (e.g., BioNTech’s
mRNA-based personalized vaccines).
2. Precision Medicine Leap:
o
BRAF/MEK inhibitors (e.g., Tafinlar + Mekinist)
account for 32% of targeted therapy sales, while biomarker testing adoption has
increased to 65% in the U.S. and EU.
o Liquid biopsies gain traction, reducing treatment
resistance risks (market for melanoma liquid assays to hit USD
1.8B by 2030).
3. Early Detection Tech:
o
AI-powered dermatoscopes (e.g., DermEngine) reduce
diagnostic delays by 30% and achieve 90% accuracy in detecting Stage 0–I
melanomas.
Competitive Intensity Heats Up
· Merck & Co. (35% share): Strengthens Keytruda’s dominance with new
adjuvant approvals for Stage IIB/C melanoma (2024).
·
Bristol-Myers Squibb (28%): Investing in the
Opdivo+Yervoy combination, which is currently in Phase III trials for rare
ocular melanoma.
·
Startups Disrupt: Companies
like NeraCare (Germany) are pioneering hyperspectral imaging for
non-invasive staging.
Regional Front-Runners
·
North
America (48% share):
U.S. leads with 90% insurance coverage for
immunotherapy.
·
Europe
(XX%): Germany’s
universal biomarker testing policy drives 15% annual growth.
·
Asia-Pacific
(XX%): Japan’s
fast-track approvals for novel therapies (e.g., Delcath’s CHEMOSAT)
fuel demand.
Patient Access Challenges
Despite progress, cost barriers persist:
·
Immunotherapy
costs USD 150,000 per year, limiting uptake in emerging markets.
·
Only 25%
of African nations include melanoma drugs in their national formularies,
compared to 85% in the EU.
Future Milestones
·
2026: First FDA-approved mRNA
melanoma vaccine (Moderna/BioNTech).
·
2028: AI platforms integrate with EHRs for
real-time treatment adjustments.
·
2030: 90% of Stage III patients receive
combo therapies as standard care.
For more
insights, visit https://clearviewmarketinsights.com/
About Clearview Market Insights:
Clearview Market Insights is a leading market research and
consulting firm providing in-depth industry analysis and strategic
recommendations for businesses worldwide.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369
Comments
Post a Comment